Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio Inc (NQ: PASG )

18.02 +0.41 (+2.33%)
Official Closing Price Updated: 7:10 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Passage Bio Inc

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021
From GlobeNewswire News Releases
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
From GlobeNewswire News Releases
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying T
From GlobeNewswire News Releases
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
From GlobeNewswire News Releases
Passage Bio Announces Pricing of Public Offering
From GlobeNewswire News Releases
Passage Bio Announces Launch of Proposed Public Offering
From GlobeNewswire News Releases
Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
From GlobeNewswire News Releases
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
From GlobeNewswire News Releases
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. 
From Business Wire News Releases
Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
From GlobeNewswire News Releases
Passage Bio Announces Gene Therapy Manufacturing Research and Development Site
From GlobeNewswire News Releases
Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
From GlobeNewswire News Releases
Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products
- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to... 
From GlobeNewswire News Releases
Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference
From GlobeNewswire News Releases
Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy
Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University’s research, which has the potential to significantly advance nascent field of gene... 
From GlobeNewswire News Releases
Passage Bio to Participate in Upcoming November Investor Conferences
From GlobeNewswire News Releases
Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights
From GlobeNewswire News Releases
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
Genetic testing, educational materials and counseling offered at no charge to patients 
From GlobeNewswire News Releases
Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
From GlobeNewswire News Releases
Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
From GlobeNewswire News Releases
Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis
From GlobeNewswire News Releases
Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into
The study conducted by the University of Pennsylvania’s Gene Therapy Program supports the potential of Passage Bio’s PBGM01 to correct the underlying genetic defect of GM1 gangliosidosis, a rare,... 
From GlobeNewswire News Releases
Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa
From GlobeNewswire News Releases
Passage Bio to Participate in Upcoming October Investor Conferences
From GlobeNewswire News Releases
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
From GlobeNewswire News Releases
Passage Bio to Participate in Citi’s 15th Annual BioPharma Virtual Conference
From GlobeNewswire News Releases
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
From GlobeNewswire News Releases
Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
From GlobeNewswire News Releases
Passage Bio Added to Russell 2000 Index
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.